Tinnitus – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Tinnitus – Pipeline Review, H2 2019’, provides an overview of the Tinnitus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Tinnitus

– The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects

– The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Tinnitus”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tinnitus

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AudioCure Pharma GmbH

Auris Medical Holding Ltd

Autifony Therapeutics Ltd

Decibel Therapeutics Inc

Gateway Biotechnology Inc

Knopp Biosciences LLC

Otonomy Inc

Sensorion SA

Sound Pharmaceuticals Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinnitus Overview

Tinnitus Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tinnitus Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinnitus Companies Involved in Therapeutics Development

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Otonomy Inc

Pragma Therapeutics SAS

Sound Pharmaceuticals Inc

Tinnitus Drug Profiles

AC-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gacyclidine SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RL-81 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Kv7.2 for Central Nervous System Disorders and Tinnitus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TNF-Alpha for Tinnitus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrandrine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinnitus Dormant Projects

Tinnitus Discontinued Products

Tinnitus Product Development Milestones

Featured News & Press Releases

Feb 06, 2018: Otonomy Announces Multiple Presentations for Tinnitus Program at Upcoming Association for Research in Otolaryngology Meeting

Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311

Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Tinnitus, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Tinnitus – Pipeline by AudioCure Pharma GmbH, H2 2019

Tinnitus – Pipeline by Auris Medical Holding Ltd, H2 2019

Tinnitus – Pipeline by Autifony Therapeutics Ltd, H2 2019

Tinnitus – Pipeline by Decibel Therapeutics Inc, H2 2019

Tinnitus – Pipeline by Gateway Biotechnology Inc, H2 2019

Tinnitus – Pipeline by Knopp Biosciences LLC, H2 2019

Tinnitus – Pipeline by Otonomy Inc, H2 2019

Tinnitus – Pipeline by Sensorion SA, H2 2019

Tinnitus – Pipeline by Sound Pharmaceuticals Inc, H2 2019

Tinnitus – Dormant Projects, H2 2019

Tinnitus – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Tinnitus, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports